Sebastian Schneeweiss, MD, ScD

Brigham and Women's Hospital and Harvard Medical School, United States

Disclosure information not submitted.

Presentation(s):

• SC-24 - Applied Sensitivity Analyses in Pharmacoepidemiology Database Studies

  Saturday, August 23, 2025
  2:30 PM - 6:00 PM ET

• SW-1B - Bridging Real-world and RCT Endpoints: Mitigating Measurement Error Bias in Time-to-event Endpoints in Studies using Oncology Real-world Data

  Sunday, August 24, 2025
  1:30 PM - 3:00 PM ET

• 2E-05 - Use of alternative study designs in evaluating comparative risks of infections among patients with moderate-to-severe psoriasis treated with newer vs. older immunomodulatory treatments

  Sunday, August 24, 2025
  4:30 PM - 4:45 PM ET

• 2F-06 - Differentiating Between Uncontrolled Confounding and Heterogenous Treatment Effects in Individualized Treatment Effect Prediction Models Using Machine Learning: Leveraging Negative Controls

  Sunday, August 24, 2025
  4:45 PM - 5:00 PM ET

• 3A-01 - Cardiovascular Effectiveness of Semaglutide: Using Real-World Data to Predict Findings of the Ongoing SOUL Cardiovascular Outcomes Trial

  Monday, August 25, 2025
  8:15 AM - 8:30 AM ET

• 3C-01 - Comparative Effectiveness of Left Atrial Appendage Occlusion versus Oral Anticoagulants in Older Atrial Fibrillation Patients

  Monday, August 25, 2025
  8:15 AM - 8:20 AM ET

• 5F-02 - US Food and Drug Administration Approval of Biologic Use in Children and Adolescents, 1965-2023

  Tuesday, August 26, 2025
  8:45 AM - 9:00 AM ET

• 6C-03 - Using Real-World Data to Predict Findings of an Ongoing Phase IV Trial: Glycemic Control of Semaglutide vs Standard of Care

  Tuesday, August 26, 2025
  2:00 PM - 2:15 PM ET